A comprehensive framework for early-onset colorectal cancer research

Eng, Cathy; Jácome, Alexandre A.; Agarwal, Rajiv; Hayat, Muhammad Hashim; Byndloss, Mariana X.; Holowatyj, Andreana N.; Bailey, Christina E.; Lieu, Christopher H.

doi:10.1016/s1470-2045(21)00588-x

Cited by 76 publications

(57 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRC Screening Guidelines do exist worldwide, but differ regionally according to the burden of the CRC in the country. Examples of the most preferred screening methods for those >50 years old are colonoscopy every 10 years, flexible sigmoidoscopy every 5 years, yearly guaiac-based faecal occult blood test, faecal immunochemical test every other year or multitargeted stool DNA every one to three years [ 26 ].…”

Section: Screening and Diagnosismentioning

confidence: 99%

Early onset colorectal cancer: Challenges across the cancer care continuum

AlZaabi

AlHarrasi²,

Al-Musalami

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Section: Screening and Diagnosismentioning

confidence: 99%

Early onset colorectal cancer: Challenges across the cancer care continuum

AlZaabi

AlHarrasi²,

Al-Musalami

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

“…Colectomy is performed to eradicate the cancerous portion of the colon, but it can lead to significant clots, blood loss, and infections. Patients may experience swelling, severe pain, and unpredictable emotional or physical stress responses as a result of the treatment methods [ 66 ]. Radiotherapy is an additional treatment option that uses advanced radiation energy to kill cancerous cells.…”

Section: Colorectal Cancer: Understanding the Backgroundmentioning

confidence: 99%

Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells

Karthika

Sureshkumar

Zehravi

et al. 2022

Life

View full text Add to dashboard Cite

Even though various treatment methods are available for cancer, the death curve is not reducing. The diagnosis of cancer at the fourth stage and drug resistance are the leading reasons for treatment failure and lower survival rates. In this review article, we summarize the possible pitfalls during cancer treatment in general, which mainly include multidrug resistance, and propose a hypothesis for colorectal cancer specifically. We also evaluate multidrug resistance in cancer in general and colorectal cancer in particular and hypothesize a concept based on combination therapy with 5-fluorouracil, curcumin, and lipids for the possible management of colorectal cancer. In addition, a hypothetical approach, combining a synthetic agent and a natural chemotherapeutic agent, to treating colorectal cancer is also discussed. This hypothesis could improve the management of colorectal cancer.

show abstract

“…Reasons for these disparities are unclear and multifactorial, but delays to diagnosis and treatment have been identified as potential factors [ 4 ]. Being a primarily unscreened population, younger adults may experience delays as a consequence of low patient awareness of alarm symptoms, hesitation to seek care, physician misdiagnosis, and poor access to care, resulting in continued tumor growth and advanced stage [ 4 , 7 , 8 ]. The consequences of delay may also differ between younger and older patients with CRC, given differences in tumour biology [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Time to diagnosis and treatment in younger adults with colorectal cancer: A systematic review

et al. 2022

View full text Add to dashboard Cite

Background The incidence of colorectal cancer is rising in adults <50 years of age. As a primarily unscreened population, they may have clinically important delays to diagnosis and treatment. This study aimed to review the literature on delay intervals in patients <50 years with colorectal cancer (CRC), and explore associations between longer intervals and outcomes. Methods MEDLINE, Embase, and LILACS were searched until December 2, 2021. We included studies published after 1990 reporting any delay interval in adults <50 with CRC. Interval measures and associations with stage at presentation or survival were synthesized and described in a narrative fashion. Risk of bias was assessed using the Newcastle-Ottawa Scale, Institute of Health Economics Case Series Quality Appraisal Checklist, and the Aarhus Checklist for cancer delay studies. Results 55 studies representing 188,530 younger CRC patients were included. Most studies used primary data collection (64%), and 47% reported a single center. Sixteen unique intervals were measured. The most common interval was symptom onset to diagnosis (21 studies; N = 2,107). By sample size, diagnosis to treatment start was the most reported interval (12 studies; N = 170,463). Four studies examined symptoms onset to treatment start (total interval). The shortest was a mean of 99.5 days and the longest was a median of 217 days. There was substantial heterogeneity in the measurement of intervals, and quality of reporting. Higher-quality studies were more likely to use cancer registries, and be population-based. In four studies reporting the relationship between intervals and cancer stage or survival, there were no clear associations between longer intervals and adverse outcomes. Discussion Adults <50 with CRC may have intervals between symptom onset to treatment start greater than 6 months. Studies reporting intervals among younger patients are limited by inconsistent results and heterogeneous reporting. There is insufficient evidence to determine if longer intervals are associated with advanced stage or worse survival. Other This study’s protocol was registered with the Prospective Register of Systematic Reviews (PROSPERO; registration number CRD42020179707).

show abstract

A comprehensive framework for early-onset colorectal cancer research

Cited by 76 publications

References 113 publications

Early onset colorectal cancer: Challenges across the cancer care continuum

Early onset colorectal cancer: Challenges across the cancer care continuum

Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells

Time to diagnosis and treatment in younger adults with colorectal cancer: A systematic review

Contact Info

Product

Resources

About